A clinical trial update for retatrutide was recorded on September 28, 2026. The study, registered as NCT06260722 and titled "Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor," also known as TRANSCEND-T2D-2, is a Phase 3 trial.
Its status is listed as active, not recruiting, meaning the study is ongoing but no longer enrolling new participants. The trial compares retatrutide with semaglutide in adults who have type 2 diabetes and inadequate glycemic control despite metformin use, with or without an SGLT2 inhibitor.
No results have been posted for this trial as of this update. This brief reports only the status change and does not describe outcomes, efficacy, or safety findings, since none were included in the available event data.
Readers can consult the official registry entry at the provided source link for further details on trial design, eligibility criteria, and future updates as the study progresses.
For more background on this compound, see the retatrutide overview.